Copyright
©The Author(s) 2021.
World J Gastroenterol. Apr 28, 2021; 27(16): 1691-1715
Published online Apr 28, 2021. doi: 10.3748/wjg.v27.i16.1691
Published online Apr 28, 2021. doi: 10.3748/wjg.v27.i16.1691
Table 2 Treatment criteria in patients with chronic hepatitis B virus and immune active phase per society guidelines
| Criteria | American Association for the Study of Liver Disease[61] | European Association for the Study of the Liver[63] | Asian Pacific Association for the study of Liver Diseases[62] |
| ALT | ≥ 2 times ULN—males 35 U/L, females 25 U/L | > 1 time ULN—40 U/L | > 2 times ULN—40 U/L |
| HBV DNA viral load | > 2000 IU/mL if HBeAg negative or > 20000 IU/mL if HBeAg positive | > 2000 IU/mL, regardless of HBeAg status | > 2000 IU/mL if HBeAg negative or > 20000 IU/mL if HBeAg positive |
| Degree of liver fibrosis/inflammation | Liver biopsy with moderate-severe inflammation or advanced liver fibrosis (F3-F4). Liver elastography or serum markers showing advanced liver fibrosis (F3-F4) | Liver biopsy, liver elastography or non-invasive testing consistent with moderate-severe fibrosis (F3-F4) | Liver biopsy with moderate-severe inflammation or advanced liver fibrosis (F3-F4). Fibroscan or serum markers showing advanced liver fibrosis (F3-F4) |
- Citation: Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715
- URL: https://www.wjgnet.com/1007-9327/full/v27/i16/1691.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i16.1691